You are here

High Frequency Dielectric Sensing Cardiac Radio Frequency Ablation Monitoring and Lesion Assessment System

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R44HL147787-02A1
Agency Tracking Number: R44HL147787
Amount: $598,321.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: NHLBI
Solicitation Number: PA21-259
Solicitation Year: 2021
Award Year: 2022
Award Start Date (Proposal Award Date): 2022-04-13
Award End Date (Contract End Date): 2024-03-31
Small Business Information
Columbia, MD 21044-4909
United States
DUNS: 079939983
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (305) 725-8105
Business Contact
Phone: (305) 725-8105
Research Institution

Atrial fibrillation (AF) affects over 6 million individuals in the USA and is a significant cause of morbidity
and mortality. Percutaneous catheter Radio Frequency Ablation (RFA) treatment of AF is the standard of
care for treatment of AF. However, current procedures have a ~50% recurrence rate, due to incomplete
ablations and carry a ~4% risk of complications, due to excessive RF energy deposition. There is an urgent
unmet clinical need to improve the safety and efficacy of cardiac RFA procedures.To address this clinical need; we are developing an intraoperative High Frequency Dielectric Sensing
Lesion Assessment system (HFDS-LAS). Our solution involves; designing the ablation electrode of an RFA
catheter as a “miniature radar” to monitor the electrical properties of the tissue adjacent to the antenna-
electrode. The system comprises; a) steerable ablation catheter with an integrated antenna-sensor ablation
electrode, b) vector network analyzer to measure tissue dielectric properties in a frequency range of 10 MHz
to 4 GHz, c) RF filter hardware to filter ablation (KHz) and measurement (MHz-GHz) frequencies and d)
intuitive graphic user interface which displays procedure parameters, state of lesion formation and warns of
adverse events at high speed and accuracy.During Phase 1 SBIR project, we prototyped a first-of-its-kind Cardiac HFDS-LAS comprising a 9.5Fr
RFA catheter with an antenna-sensor electrode, band selective filter hardware and a prototype Guidance
User Interface (GUI). In bench and animal (n=5) testing, we definitively demonstrated feasibility of
intraoperatively monitoring cardiac RFA procedures to accurately: confirm and quantify electrode-tissue
electrical contact; characterize tissue; confirm and assess lesion formation/extent of ablation; and predict
micro-bubbles and steam-pops to titrate RF power to safely and efficaciously deliver atrial lesions. The
system is compatible with all EP cathlab equipment e.g. cardiac mapping systems, etc., with no changes to
cardiac RFA procedural workflow.During Phase 2 of the project, we will optimize and test to finalize design of a clinical grade HFDS-LAS,
comprising 8.5Fr catheter with omnidirectional antenna-sensor electrode, high fidelity filter hardware and a
GUI displaying tissue type, lesion formation and critical procedure parameters. The system will undergo
verification and performance testing in vitro and validation testing in animals to definitively quantify system
performance; and enable submit a pre submission and a submission to the FDA for IDE clearance towards
a safety and efficacy clinical trial.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government